240 related articles for article (PubMed ID: 10543732)
1. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
3. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
Onodera Y; Uchida Y; Tanaka M; Sato K
J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
7. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
[TBL] [Abstract][Full Text] [Related]
8. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
9. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
11. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
[TBL] [Abstract][Full Text] [Related]
12. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
13. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
14. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Pestova E; Millichap JJ; Noskin GA; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
[TBL] [Abstract][Full Text] [Related]
15. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
16. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
17. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
Harding I; Simpson I
J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
[TBL] [Abstract][Full Text] [Related]
19. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
Fukuda H; Hiramatsu K
Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
[TBL] [Abstract][Full Text] [Related]
20. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS; Ambler J; Mehtar S; Fisher LM
Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
